Trial Profile
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Niraparib (Primary) ; Niraparib
- Indications Solid tumours
- Focus Pharmacokinetics
- Acronyms TABLET
- Sponsors GlaxoSmithKline; GSK; TESARO
- 12 Sep 2023 Results assessing the relative bioavailability(BA; Stage 1 [S1]) and bioequivalence (BE; Stage 2 [S2])between niraparib tablets and capsules, presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 06 Jun 2023 Results assessing the relative bioavailability (BA; Stage 1 [S1]) and bioequivalence (BE; Stage 2 [S2]) between niraparib tablets and capsules, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 21 Jul 2022 Planned End Date changed from 16 Jun 2022 to 8 May 2023.